phosphorylation

Astrocytes: From Metabolism to Cognition

Different brain cell types exhibit distinct metabolic signatures that link energy economy to cellular function. Astrocytes and neurons, for instance, diverge dramatically in their reliance on glycolysis versus oxidative phosphorylation, underscoring that metabolic fuel efficiency is not uniform across cell types. A key factor shaping this divergence is the structural organization of the mitochondrial respiratory chain into supercomplexes. Specifically, complexes I (CI) and III (CIII) form a CI–CIII supercomplex, but the degree of this assembly varies by cell type. In neurons, CI is predominantly integrated into supercomplexes, resulting in highly efficient mitochondrial respiration and minimal reactive oxygen species (ROS) generation. Conversely, in astrocytes, a larger fraction of CI remains unassembled, freely existing apart from CIII, leading to reduced respiratory efficiency and elevated mitochondrial ROS production. Despite this apparent inefficiency, astrocytes boast a highly adaptable metabolism capable of responding to diverse stressors. Their looser CI–CIII organization allows for flexible ROS signaling, which activates antioxidant programs via transcription factors like Nrf2. This modular architecture enables astrocytes not only to balance energy production but also to support neuronal health and influence complex organismal behaviors.

Towards Human Systems Biology of Sleep/Wake Cycles: Phosphorylation Hypothesis of Sleep

The field of human biology faces three major technological challenges. Firstly, the causation problem is difficult to address in humans compared to model animals. Secondly, the complexity problem arises due to the lack of a comprehensive cell atlas for the human body, despite its cellular composition. Lastly, the heterogeneity problem arises from significant variations in both genetic and environmental factors among individuals. To tackle these challenges, we have developed innovative approaches. These include 1) mammalian next-generation genetics, such as Triple CRISPR for knockout (KO) mice and ES mice for knock-in (KI) mice, which enables causation studies without traditional breeding methods; 2) whole-body/brain cell profiling techniques, such as CUBIC, to unravel the complexity of cellular composition; and 3) accurate and user-friendly technologies for measuring sleep and awake states, exemplified by ACCEL, to facilitate the monitoring of fundamental brain states in real-world settings and thus address heterogeneity in human.

Elucidating the mechanism underlying Stress and Caffeine-induced motor dysfunction using a mouse model of Episodic Ataxia Type 2

Episodic Ataxia type 2 (EA2), caused by mutations in the CACNA1A gene, results in a loss-of-function of the P/Q type calcium channel, which leads to baseline ataxia, and attacks of dyskinesia, that can last a few hours to a few days. Attacks are brought on by consumption of caffeine, alcohol, and physical or emotional stress. Interestingly, caffeine and stress are common triggers among other episodic channelopathies, as well as causing tremor or shaking in otherwise healthy adults. The mechanism underlying stress and caffeine induced motor impairment remains poorly understood. Utilizing behavior, and in vivo and in vitro electrophysiology in the tottering mouse, a well characterized mouse model of EA2, or WT mice, we first sought to elucidate the mechanism underlying stress-induced motor impairment. We found stress induces attacks in EA2 though the activation of cerebellar alpha 1 adrenergic receptors by norepinephrine (NE) through casein kinase 2 (CK2) dependent phosphorylation. This decreases SK2 channel activity, causing increased Purkinje cell irregularity and motor impairment. Knocking down or blocking CK2 with an FDA approved drug CX-4945 prevented PC irregularity and stress-induced attacks. We next hypothesized caffeine, which has been shown to increase NE levels, could induce attacks through the same alpha 1 adrenergic mechanism in EA2. We found caffeine increases PC irregularity and induces attacks through the same CK2 pathway. Block of alpha 1 adrenergic receptors, however, failed to prevent caffeine-induced attacks. Caffeine instead induces attacks through the block of cerebellar A1 adenosine receptors. This increases the release of glutamate, which interacts with mGluR1 receptors on PC, resulting in erratic firing and motor attacks. Finally, we show a novel direct interaction between mGluR1 and CK2, and inhibition of mGluR1 prior to initiation of attack, prevents the caffeine-induced increase in phosphorylation. These data elucidate the mechanism underlying stress and caffeine-induced motor impairment. Furthermore, given the success of CX-4945 to prevent stress and caffeine induced attacks, it establishes ground-work for the development of therapeutics for the treatment of caffeine and stress induced attacks in EA2 patients and possibly other episodic channelopathies.

Unique Molecular Regulation of Prefrontal Cortex Confers Vulnerability to Cognitive Disorders

The Arnsten lab studies molecular influences on the higher cognitive circuits of the dorsolateral prefrontal cortex (dlPFC), in order to understand mechanisms affecting working memory at the cellular and behavioral levels, with the overarching aim of identifying the actions that render the dlPFC so vulnerable in cognitive disorders. Her lab has shown that the dlPFC has unique neurotransmission and neuromodulation compared to the classic actions found in the primary visual cortex, including mechanisms to rapidly weaken PFC connections during uncontrollable stress. Reduced regulation of these stress pathways due to genetic or environmental insults contributes to dlPFC dysfunction in cognitive disorders, including calcium dysregulation and tau phosphorylation in the aging association cortex. Understanding these unique mechanisms has led to the development of a new treatment, IntunivTM, for a variety of PFC disorders.

STAT3 PHOSPHORYLATION INHIBITORS WITH PYRIMETHAMINE AND PIOGLITAZONE PHARMACOPHORES: AN <EM>IN SILICO</EM> AND <EM>IN VITRO</EM> APPROACH FOR DRUG REPURPOSING

FENS Forum 2026

DIFFERENTIAL MODULATION OF GLYRΑ3 BY SEC8 PROTEIN: IMPACT OF PHOSPHORYLATION OF RESIDUE S346 ON THE INTERACTION OF SEC8 WITH THE GLYRΑ3

FENS Forum 2026

PHOSPHORYLATION-DEPENDENT REGULATION OF GABA TYPE A RECEPTORS: IMPLICATIONS FOR RECEPTOR FUNCTION AND SENSITIVITY TO ALLOSTERIC MODULATORS

FENS Forum 2026

TAU PHOSPHORYLATION AFTER HEAVY ALCOHOL CONSUMPTION DURING ADOLESCENCE IN P301S MICE

FENS Forum 2026

WIPI2 PHOSPHORYLATION MEDIATES EARLY INTRA-AXONAL AUTOPHAGY DYSFUNCTION IN ALZHEIMER’S DISEASE

FENS Forum 2026

PRELIMINARY FINDINGS ON SEX DIFFERENCES IN ABNORMAL TAU PROTEIN PHOSPHORYLATION IN ALZHEIMER´S DISEASE PATIENTS

FENS Forum 2026

REGULATION OF CREB PHOSPHORYLATION BY DOPAMINE AND CYCLIC AMP IN THE DEVELOPING AVIAN RETINA: ANALYSIS OF DIFFERENT SIGNALING PATHWAYS INVOLVING CALCIUM AND SOLUBLE ADENYLYL CYCLASE

FENS Forum 2026

DYNAMIC CHANGES IN THE THALAMIC PROTEOME IN FETAL GROWTH RESTRICTED PIGLETS REVEALS EARLY NEUROPROTECTIVE RESPONSES FOLLOWED BY A DECLINE IN OXIDATIVE PHOSPHORYLATION

FENS Forum 2026

ACTIVITY-DEPENDENT MUSCARINIC SIGNALLING CONTROLS PKC PHOSPHORYLATION OF MUNC18-1 AND SNAP-25 TO REGULATE NEUROTRANSMISSION AT THE NEUROMUSCULAR JUNCTION

FENS Forum 2026

TARGETING OF TUBULIN-ALPHA 4A POLYGLUTAMYLATION TO MODULATE TAU-MICROTUBULE INTERACTIONS AND PREVENT TAU HYPERPHOSPHORYLATION IN ALZHEIMER'S DISEASE

FENS Forum 2026

DIFFERENTIAL REGULATION OF CRMP2 PHOSPHORYLATION AT SER522 AND THR514 IN EXPERIMENTAL MODELS OF CEREBRAL ISCHEMIA

FENS Forum 2026

ALPHA-SYNUCLEIN PHOSPHORYLATION DIRECTS TRAFFICKING OF THE V-SNARE SYNAPTOBREVIN-2

FENS Forum 2026

AMYLOID-Β OLIGOMER BINDING TRIGGERS TAU HYPERPHOSPHORYLATION AND MICROGLIAL ACTIVATION IN ADULT HUMAN BRAIN SLICE

FENS Forum 2026

TARGETING TAU AGGREGATION AND PHOSPHORYLATION WITH DDMC, A NON-ANTIBIOTIC TETRACYCLINE

FENS Forum 2026

PROBING EFFECTS OF ANESTHESIA AND EXERCISE ON TAU PHOSPHORYLATION

FENS Forum 2026

Ultrasensitive immunoassays reveal novel insights into alpha-synuclein phosphorylation and subcellular distribution in PFF-inoculated wild-type mice

FENS Forum 2024

Impact of the AT8 epitope phosphorylation on Tau aggregation, propagation, and neurotoxicity

FENS Forum 2024

Effects of PKA-mediated phosphorylation in the glycine receptor alpha 3K variant

Glutamatergic and cytoskeletal protein phosphorylation associated with the antidepressant-like properties of the iron chelator deferiprone in a mouse model of depression

Microglial TNFα orchestrates protein phosphorylation during the sleep period and controls homeostatic sleep

ERK phosphorylation in DG and NACC after morphine CPP extinction. Involvement of morphine encapsulation in liposomes

PKA-dependent SNAP-25 and Syn-1 phosphorylation are differently regulated by the neuromuscular activity

Regulation of the DNA damage response by E2F4 phosphorylation in its T249/T251 conserved motif and Alzheimer’s disease

The role of activity-dependent phosphorylation in the presynaptic function of α-synuclein

Functional implications of traumatic brain injury-induced changes in serine/threonine kinase activity and peptide phosphorylation in mouse cortex

FENS Forum 2024

Characterizing LRRK2 in varying states of phosphorylation

Inhibition of p38MAPK-dependent phosphorylation of E2F4 in its T249/T251 motif prevents DNA damage-induced death in N2a-derived neurons

FENS Forum 2024

Methylcobalamin promotes Ras-mediated Akt phosphorylation to induce anti-inflammatory phenotype in macrophages following peripheral nerve injury: A rat model study

FENS Forum 2024

Modulation of AKT and ribosomal S6 protein phosphorylation by dopamine receptors and cyclic AMP in the developing retina

FENS Forum 2024

Prediabetes and type 2 diabetes affect tau phosphorylation patterns in murine models of Alzheimer’s disease

FENS Forum 2024

Type one diabetes modifies tau phosphorylation patterns and worsens cognitive impairment in the APP/PS1 mouse model of Alzheimer’s disease

FENS Forum 2024